Study claims cervical cancer vaccine economically viable

A DRUG company study claims to prove it makes economic sense for Ireland to begin a national vaccination programme against cervical cancer.

Research by GlaxoSmithKline found it would work out cheaper for the State to pay €345 per vaccine than to fund the €10.3 million it costs to diagnose and treat cervical cancer annually.

The results of the study will be presented at a meeting of the International Society of Pharmacoeconomics and Outcomes Research in Dublin today. A separate study is also being carried out for the Government by the National Centre for Pharmacoeconomics.